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Renal denervation (RDN) is a catheter-based ablation procedure designed to treat resistant hypertension 
(RH). The objective of our study is to determine the effect of RDN on blood pressure and renal function in 
patients with RH in comparison to medical therapy alone. We performed an extensive literature search 
for randomized control trials (RCT) reporting office and 24 hr. blood pressure changes and estimated 
glomerular filtration rate (eGFR) at baseline and 6 months. We calculated a weighted standardized 
mean difference of blood pressure and renal outcomes between RDN and control groups using random 
effects models. Our search yielded 608 studies of which we included 15 studies for the final analysis. 
A total of 857 patients were treated with RDN and 616 patients treated with medical therapy ± sham 
procedure. Only 5 studies were double-blinded RCT with sham control. The adjusted standardized mean 
difference in the change in office based systolic and diastolic pressures (p = 0.18; p = 0.14); 24 hr. systolic 
and diastolic pressures (p = 0.20; p = 0.18); and eGFR (p = 0.20) from baseline to 6 months is statistically 
insignificant with significant heterogeneity. Subgroup analysis showed that among sham controlled 
trials, 24 hr. systolic blood pressure showed a modest but statistically significant benefit favoring renal 
denervation in patients with RH. Our meta-analysis of 15 RCTs showed no significant benefit of RDN on 
blood pressure control in patients with resistant hypertension. subgroup analysis of sham control studies 
showed a modest benefit in 24 hr. systolic blood pressure at 6 months with RDN.
Resistant hypertension (RH) is defined as blood pressure that remains above guideline-directed goal despite the 
concurrent use of at least three antihypertensive agents of different classes, one of which is a diuretic1. The prev-
alence of RH based on recent studies is ranging from as low as 12.8%2, while others have shown RH to be up to 
25–30% in the general hypertensive population3. A 2012 study by Dougherty et al. showed the incidence of resist-
ant hypertension to be 1.9% within 1.5 years of newly diagnosed hypertensive patients undergoing treatment4.
When hypertension remains uncontrolled with lifestyle changes and antihypertensive medications, renal den-
ervation has been a proposed intervention to aid in the treatment of RH since it was first used a decade ago5. 
Since then, there have been numerous studies and randomized control trials to evaluate the effectiveness of this 
procedure in treating RH with variable results.
One of the most recent meta-analysis w by Fadl Elmula et al. did not show any significant effect on blood pres-
sure in patients with RH following renal denervation6. Over the past year, multiple randomized control trials eval-
uating the effect of renal denervation on RH showed promising results including: WAVE-IV7, SPYRAL HTN-ON 
MED8, INSPiRED9, and a Polish study by Warchol-Celinska et al.10 We, therefore, conducted a systematic review 
and meta-analysis based on randomized control trials to assess the efficacy of renal denervation in patients with 
RH at 6 months in comparison to medical therapy alone ± sham procedure.
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Results
Our search yielded 608 studies. After exclusion of duplicates, 456 studies remained of which we included 15 studies 
for the final analysis (Fig. 1). A total of 857 patients were treated with renal denervation and 616 patients treated 
with medical therapy ± sham procedure. Of the included studies, only 5 were double blinded randomized control 
trials with sham control7,8,11–13, while the remaining 10 trials were open-label clinical trials with a control group 
treated with optimal medical therapy9,10,14–21. Radiofrequency (RF) ablation was performed in all trials except the 
WAVE-IV7, where ultrasound energy based (US) ablation was performed. Only 13 studies reported a mean change 
in office based systolic and diastolic blood pressures, and 14 studies reported a mean change in 24 hr. systolic and 
diastolic blood pressure between baseline and 6 months post-randomization. Only 11 studies reported a change in 
estimated glomerular filtration rate (eGFR) between baseline and 6 months post-randomization in the treatment 
and control groups. The baseline characteristics of the included studies are included in Table 1. Baseline char-
acteristics of study participants of the included studies are reported in the Supplementary Tables S1 and S2. The 
overall quality of the included randomized control trials was high based on the Jadad scale except for the study by 
Warchol-Celinska et al.10 which was a low-quality study (Supplementary Table S3).
The change in blood pressure (24 hr. and office) at 6 months and renal function in patients in the renal den-
ervation (RDN) and the control group for each study is listed in Supplementary Table S4. In the pooled analysis, 
the unadjusted change in office blood pressure (mmHg) in the RDN group was −14.65 ± 22.29 (systolic) and 
−6.88 ± 11.89 (diastolic) vs −11.63 ± 22.30 (systolic) and −4.94 ± 11.97 in the control group. The unadjusted 
change in 24 hr. blood pressure (mmHg) in the RDN group was −7.53 ± 15.14 (systolic) and −4.64 ± 9.18 (dias-
tolic) vs −5.72 ± 15.12 (systolic) vs −3.71 ± 8.95 (diastolic) in the control group. The unadjusted pooled change in 
eGFR (mL/min/1.73 m2) at 6 months in the RDN group was −1.7 ± 11.75 vs −2.39 ± 11.67 in the control group.
Efficacy of renal denervation on systolic blood pressure. The adjusted standardized mean difference 
in the change in systolic blood pressure (office) at 6 months between RDN and control groups was −0.24 (95% 
confidence interval (CI) −0.60–0.11, p = 0.18) which is statistically insignificant. Subgroup analysis showed no 
statistical significance in both the sham controlled (p = 0.81) and non-sham controlled studies (p = 0.20). There 
was a high degree of heterogeneity noted among the studies (I2 = 87.5%). The results are summarized in Fig. 2. 
Meta regression analysis showed that underlying coronary artery disease (β = −0.02, p = 0.02) influenced the 
primary outcome (Supplementary Table S5).
The adjusted standardized mean difference in the change in systolic blood pressure (24 hr.) at 6 months 
between RDN and control groups was −0.22 (95% CI −0.55–0.11, p = 0.20), which was statistically insignif-
icant. However, subgroup analysis among sham control studies showed statistical significance favoring renal 
denervation (p = 0.02). A high degree of heterogeneity was noted among the studies included in the main anal-
ysis (I2 = 85.8%). The results are summarized in Fig. 3. However, the subgroup of sham control studies had a 
low degree of heterogeneity, which likely contributed to the statistical significance achieved in this subgroup. 
Meta-regression analysis showed that underlying coronary artery disease (β = −0.034; p = 0.001) significantly 
influenced the change in 24 hr. systolic blood pressure reported by the studies, suggesting that the lower preva-
lence of coronary artery disease positively affected the reduction in 24 hr. systolic blood pressure (Supplementary 
Table S5).
Efficacy of Renal denervation on diastolic blood pressure. The adjusted standardized mean differ-
ence in the change in diastolic blood pressure (office) at 6 months between RDN and control groups was −0.34 
(95% CI −0.80–0.11, p = 0.14) which was not statistically significant. Subgroup analysis showed no difference 
in both the sham controlled (p = 0.52) and non-sham controlled studies (p = 0.16). There was a high degree 
Figure 1. PRISMA Flow Chart.
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of heterogeneity noted among the studies (I2 = 92.3%), which likely accounted for the lack of difference noted 
between both groups. The results are summarized in Fig. 4. Meta regression analysis showed that underlying cor-
onary artery disease (β = −0.03, p = 0.02) and sham controlled study (β = 1.23, p = 0.01) influenced the change 
in diastolic blood pressure (office) reported by the studies (Supplementary Table S5). This suggests that the lower 
prevalence of coronary artery disease and sham control study design contributed to the lack of difference noted 
between both groups.
The adjusted standardized mean difference in the change in diastolic blood pressure (24 hr.) at 6 months 
between RDN and control groups was −0.19 (95% CI −0.47–0.09, p = 0.18) which was not statistically signifi-
cant. Subgroup analysis showed no statistical significance in both the sham controlled (p = 0.10) and non-sham 
controlled studies (p = 0.18). There was a high degree of heterogeneity noted among the studies (I2 = 79.6%). The 
sham control studies showed no heterogeneity (I2 = 0%), however, the result remained unchanged. The results 
are summarized in Fig. 5. Meta regression analysis showed that underlying coronary artery disease (β = −0.03, 
p = 0.005) influenced the change in 24 hr. diastolic blood pressure reported by the studies (Supplementary 
Table S5).
Effect of renal denervation on renal function (eGFR). The adjusted standardized mean difference in 
the change in eGFR at 6 months between RDN and control groups was 0.11 (95% CI −0.06–0.29, p = 0.20) which 
was statistically insignificant. Subgroup analysis showed no statistical significance in both the sham controlled 
(p = 0.69) and non-sham controlled studies (p = 0.07). There was a low degree of heterogeneity noted among the 
studies (I2 = 32.9%). The results are summarized in Fig. 6. Meta regression analysis showed that none of the tested 
covariates influenced the change in eGFR reported by the studies (Supplementary Table S5).
Risk of bias across individual studies was estimated for the five outcomes using Deek’s funnel plot. The funnel 
plot for the meta-analysis showed significant asymmetry suggesting publication bias. However, the trim-and-fill 
method showed no need for adjusting the effect size for the meta-analysis.
Author study acronym
year of 
publication Location Study Design
Total 
sample 
size
N 
(RDN)
N 
(control)
Renal denervation 
group Control group
Drug adherence 
assessment Catheter
Renal 
Denervation 
Ablation
Esler et al.16 Symplicity HTN 2 2010
Europe, 
Australia
Open label 
multicenter trial 82 49 35
Renal Denervation + 
Medical therapy Medical Therapy Diary Symplicity Radiofrequency
Bhatt et al.11 Symplicity HTN 3 2014
United 
states
Double blind 
multicenter trial 535 364 171
Renal Denervation + 
Medical therapy
Sham + Medical 
Therapy Diary Symplicity Radiofrequency
Fadl Elmula 
et al.17 OSLO RDN 2014 Europe
Open label single 
center trial 19 9 10
Renal Denervation + 
Medical therapy Medical Therapy
Witnessed 
Medication 
Intake
Symplicity Radiofrequency
Rosa et al.20 PRAGUE-15 2015 Europe Open label multicenter trial 106 52 54
Renal Denervation + 
Medical therapy
Medical Therapy 
(including 
Spironolactone)
Plasma Drug 
Concentration Symplicity Radiofrequency
Azizi et al.14 DENERHTN 2015 Europe Open label multicenter trial 96 48 48
Renal Denervation + 
Medical therapy Medical Therapy
Morisky 
Medication 
Adherence Scale
Symplicity Radiofrequency
Desch et al.12 Symplicity-Flex 2015 Europe Double blind single center trial 71 32 35
Renal Denervation + 
Medical therapy
Sham + Medical 
Therapy Interview
Symplicity 
Flex Radiofrequency
Schneider  
et al.21 ISAR-denerve 2015 Europe
Open label single 
center trial 18 9 9
Renal Denervation + 
Medical therapy Medical Therapy Logbook
Symplicity 
Flex Radiofrequency
Kario et al.18 Symplicity HTN-Japan 2015 Asia
Open label 
multicenter trial 41 22 19
Renal Denervation + 
Medical therapy Medical Therapy Diary Symplicity Radiofrequency
Mathiassen 
et al.13 ReSET 2016 Europe
Double blind 
single center trial 69 36 33
Renal Denervation + 
Medical therapy
Sham + Medical 
Therapy Diary Symplicity radiofrequency
Oliveras et al.19 DENERVHTA 2016 Europe Open label multicenter trial 27 11 13
Renal Denervation + 
Medical therapy
Medical Therapy 
(including 
Spironolactone)
Haynes-Sackett 
Test Symplicity Radiofrequency
de Jager et al.15 Sympathy 2017 Europe Open label multicenter trial 139 95 44
Renal Denervation + 
Medical therapy Medical Therapy
Plasma Drug 
Concentration Symplicity Radiofrequency
Jacobs et al.9 INSPiRED 2017 Europe Open label multicenter trial 15 6 9
Renal Denervation + 
Medical therapy Medical Therapy
Morisky 
Medication 
Adherence Scale
EnligHTN Radiofrequency
Schmeider 
et al.7 WAVE-IV 2017 Europe
Double blind 
multicenter trial 81 42 39
Renal Denervation + 
Medical therapy Medical Therapy
Urine Toxicology 
Analysis
Surround 
Sound System Ultrasound
Warchol-
Celinska  
et al.10
No Acronym 2018 Europe Open label single center trial 60 30 30
Renal Denervation + 
Medical therapy Medical Therapy
Morisky 
Medication 
Adherence Scale
Symplicity Radiofrequency
Kandazari 
et al.8
SPYRAL HTN-
ON MED 2018
North 
America, 
Europe, 
Australia, 
Asia
Double blind 
multicenter trial 80 38 42
Renal Denervation + 
Medical therapy
Sham + Medical 
Therapy
Plasma Drug 
Concentration
Symplicity 
Spyral Radiofrequency*
Table 1. Design features of controlled trials included in the meta-analysis. RDN: Renal denervation. *Renal 
Denervation performed in the main renal artery + distal branches of renal artery.
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Discussion
Our meta-analysis of high-quality randomized control trials (Table S3) shows no significant benefit of RDN over 
medical therapy in reducing blood pressure in patients with RH. There was however a modest benefit in 24 hr. 
systolic blood pressure reduction noted with RDN in a subgroup of sham controlled randomized control trials.
Figure 2. Adjusted standardized mean difference in office systolic blood pressure after renal denervation.
Figure 3. Adjusted standardized mean difference in 24 hr. systolic blood pressure after renal denervation.
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Sham controlled randomized control trials have a semi-blinded design which is aimed to negate patient and 
physician-related confounders on the results as described previously in the literature22–24. A Sham procedure typi-
cally involves an invasive procedure performed in the patients randomized to the control group. However, perfect 
blinding is infrequently achieved. Previously, an inverse trend was most evident among the non-sham controlled 
Figure 4. Adjusted standardized mean difference in office diastolic blood pressure after renal denervation.
Figure 5. Adjusted standardized mean difference in 24 diastolic blood pressure after renal denervation.
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randomized controls, predominantly noted in the DENERVHTA trial19 and the Oslo RDN trial17. However, the 
newer trials8–10 have shown a trend towards improved blood pressure control with renal denervation in compar-
ison to medical therapy alone.
Significant heterogeneity was observed when all the included studies were analyzed together. The differences 
in blood pressure changes could in part be explained by differences in study design, type of control group and 
type of RDN procedure performed. It is widely believed that the experience of an operator plays a major role 
in the success of the procedure. In the initial trials, patients were enrolled from centers with very low operator 
volume which probably affected the success of the procedure. However over a period of time, since the first trial 
(Symplicity HTN 216) was performed in 2010, operators have become more proficient with the procedure leading 
to better outcomes. This also explains the heterogeneity of the results among the trials. With the exception of the 
change in 24 hr. systolic blood pressure, subgroup analysis (Sham vs No sham) and meta-regression analysis did 
not change the significance of blood pressure and renal function outcomes between RDN and control groups. 
The discrepancies observed between changes in 24 hr. blood pressure and office blood pressure between the two 
groups could be explained by “regression to the mean” effect, which occurs as a result of using specified office 
blood pressure thresholds while enrolling patients in these trials25. Sham control studies allow accounting for 
potential confounding factors including “regression to the mean effect”, the placebo effect of the procedure and 
improved medication adherence after renal denervation.
Most trials included in our analysis showed an improvement in blood pressure in the control group during the 
course of the trial. This could be attributed to the following reasons (1) Placebo effect in patients who underwent 
sham controlled procedures. (2) Improvement in adherence to medications as all the patients in the trials was 
monitored using medication adherence tools such as witnessed medication intake, maintenance of diary, assess-
ment of plasma drug concentration, etc. and (3) Recruiting patients who weren’t maximized on medical therapy.
The Symplicity Catheter system (Ardian, Mountain View, CA, USA) is commonly used in contemporary prac-
tice. However it has several limitations including (1) presence of single electrode leading to longer ablation time, 
(2) presence of unipolar electrode makes a selection of ablation site challenging and (3) inability to ablate deep 
renal sympathetic nerve due to low radiofrequency power of the catheter limiting the penetration depth. To over-
come these limitations, Symplicity Spyral catheter system (Medtronic, Galway, Ireland) and EnligHTN catheter 
system (St. Jude Medical, Saint Paul, MN) were introduced. They are multi-electrode catheters containing 4 elec-
trodes and can simultaneously ablate 4 locations at the same time. Results from SPYRAL HTN-OFF MED and 
SPYRAL HTN-ON MED8 trials showed a significant reduction in blood pressure with RDN. The use of multiple 
catheter systems could potentially contribute to the heterogeneity noted in our analysis.
The adjusted pooled analysis of the 5 sham controlled studies showed a modest but significant benefit in the 
mean difference in 24 hr. systolic blood pressure change at 6 months which is contrary to the prior meta-analysis 
published26. The significance was predominantly driven by SPYRAL-HTN-ON MED trial8. The renal denervation 
procedure (using RF ablation) performed in this trial targeted branch vessels beyond the proximal main renal 
artery which was unique. Animal studies have shown a greater reduction in renal norepinephrine levels with RF 
ablation if the distal extra-renal artery branches were targeted27. This hypothesis was further tested by Petrov et al. 
Figure 6. Adjusted standardized mean difference in estimated glomerular filtration rate after renal denervation.
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in a non-randomized study (N = 119) which compared the efficacy of blood pressure reduction comparing con-
ventional renal artery denervation strategy to a novel renal denervation strategy that targets the distal branches 
of the renal artery in addition to the proximal renal artery. They showed a greater decrease in office and 24 hr. 
systolic and diastolic blood pressure among the patients who underwent the novel procedure compared to the 
conventional procedure. This technique of radiofrequency RDN may explain the predominantly greater reduc-
tion in blood pressure noted in the RDN group in the SPYRAL-HTN-ON MED trial.
RADIOSOUND-HTN trial28 was performed to test head to head comparison between US ablation, conven-
tional RF ablation of main renal arteries and RF ablation of main + side branches of renal arteries. The study 
showed that significantly higher reduction in ambulatory blood pressure with US ablation compared to conven-
tional RF ablation of main renal arteries. However, no difference in blood pressure reduction was noted between 
patients who underwent US ablation compared to patients who underwent RF ablation of main and side branches 
of renal arteries. This further explains the degree of heterogeneity noted in our analysis.
A predominant confounder in randomized control trials evaluating the efficacy of a novel therapy is the med-
ication adherence among study participants. In this instance, if the medication adherence significantly improves 
after the patient undergoes renal denervation; the true effect of the procedure would be difficult to estimate. 
Among the 15 included studies, only four studies used robust methods to assess medication adherence using 
witnessed medication intake17 or plasma drug concentration8,15,20 for a total of 344 patients (approximately 24% 
of the total study population). The remaining 11 studies assessed medication adherence using compliance diary 
or validated questionnaires. Medication non-adherence is noted among 50% of hypertensive patients and its 
prevalence increases especially in patients with RH. Accurate assessment of medication non-adherence is difficult 
given the invasive nature of the tests and incorporation into routine practice remains a challenge given the tests 
are cost-intensive.
We have also shown that patients who underwent RDN had no significant changes in renal function (eGFR) 
compared to the medical therapy group at 6 months post-renal denervation, supporting the safety profile of the 
procedure. Our findings are consistent with prior published studies6,29. The positive results noted in the newer 
trials did not affect the overall result of the meta-analysis.
Limitations
The meta-analysis reported here combines data across studies in order to estimate treatment effects with more 
precision than is possible in a single study. Limitations include incorporating studies with different control arms 
and designs to increase the study population and maximizing the likelihood of estimating a treatment effect. 
However, the results of the subgroup analyses would be considered more meaningful given the lower heterogene-
ity. This specifically applies to the pooled analysis of 5 studies which showed a modest improvement in 24 systolic 
blood pressures with renal denervation. Publication bias might account for some of the effects we observed. 
Smaller trials are, in general, analyzed with less methodological rigor than larger studies, and an asymmetrical 
funnel plot suggests that selective reporting may have led to an overestimation of effect sizes in small trials. The 
lack of individual participant level data for meta-analysis and subgroup analysis is a limitation of our study. Given 
the nature of meta-analysis, the inherent weakness of the individual studies will be inherited in our study. The var-
iability of expertise among all the physicians performing renal denervation could potentially affect the outcome 
of the procedure, thereby the overall outcome of the individual trials.
Materials and Methods
Data sources and searches. An extensive electronic search of Embase, Scopus, Web of Science, PubMed, 
and manual review of the literature was performed for relevant articles using the following search terms: “renal 
denervation”, “renal sympathetic denervation”, and “resistant hypertension”. The search was restricted to publica-
tions in English and the final search was performed till from Jan 2008 to June 2018 (Supplementary data).
study selection. Studies were included if they satisfied the following criteria: (1) Age of the study popula-
tion >18 yrs.; (2) Original randomized control trials comparing renal denervation with medical therapy ± sham 
procedure, (3) Published a detailed study protocol, (4) Follow-up duration of ≥6months, (5) Patient population 
diagnosed with resistant hypertension on ≥3 blood pressure medications, (6) Reported estimated glomerular 
filtration rate (eGFR), average office or ambulatory systolic and diastolic blood pressure at baseline and 6 months 
following intervention, and (7) Reported characteristics of the overall study population. Studies were excluded in 
case of partial/complete overlap of the study population with a study already included in the analysis and also in 
cases of incomplete or incorrect reporting of data. All eligible studies complied with Consolidated Standards of 
Reporting Trials (CONSORT) quality criteria30.
Data extraction and quality assessment. The initial search was performed by two reviewers (PA; JS), 
and studies were selected for inclusion by mutual consensus. In case of disagreement, a third reviewer (RA) 
resolved disagreements through discussion to achieve a consensus. Once the studies were selected for inclusion, 
the data were screened to meet the inclusion criteria and thereafter the following data points were extracted: num-
ber of anti-hypertensive medications, class of anti-hypertensive medications used, eGFR, average office or ambu-
latory systolic and diastolic blood pressure at baseline and 6 months following the intervention. Additionally, 
cumulative demographic and baseline characteristics of the patient population included in the study were also 
extracted. The quality of included studies was assessed using the Jadad scale for randomized control trials31. 
When both intention to treat and per protocol outcomes were reported by the authors, we only considered inten-
tion to treat values for our analysis. We directly contacted the authors when additional information was missing 
from the initial studies.
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Data synthesis and Analysis. Continuous variables are presented as mean and standard deviation and cat-
egorical data as percentages. The aim of our analysis was to assess the change in blood pressure (24 hr. and office 
measured) and renal function in patients who underwent renal denervation in comparison to patients on optimal 
medical therapy. We calculated an unadjusted pooled change in eGFR, office and 24 hr. blood pressure in both 
renal denervation and control groups. We calculated a weighted standardized mean difference among outcomes 
between the renal denervation group and control group with random effects models (DerSimonian and Laird). 
Statistical heterogeneity was defined as I2 statistic value greater than 50%. Publication bias was visually assessed 
using Deek’s funnel plot followed by a trim-and-fill procedure. The Deek’s funnel plot utilizes regression of diag-
nostic log odd’s ratio against 1/square root (effective sample size) and further weighting by effective sample size. 
A p-value of the slope coefficient of <0.10 indicated asymmetry and thereby publication bias. The significance 
of asymmetry in the funnel plot will be assessed using Eggers test and a trim-and-fill test will be performed if 
applicable to correct asymmetry32,33. We performed a sensitivity analysis by type of control arm (sham vs no sham 
controlled).
Meta-regression analysis was performed to identify potential sources of heterogeneity. We performed 
meta-regression for covariates including sample size (less or more than 100), region of study, year of publica-
tion, quality of study, sham vs no sham controlled, age, gender, body mass index, proportion of patients with 
hypertension, coronary artery disease and diabetes mellitus to identify potential sources of heterogeneity. 
This meta-analysis was performed in compliance with Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) guidelines34. All the above analyses were performed in R, version 3.4.3, using “mada” 
package.
Conclusion
Our meta-analysis of 15 randomized control trials showed no significant benefit of renal denervation on blood 
pressure control in patients with resistant hypertension. Subgroup analysis of sham control studies showed a 
modest benefit in 24 hr. systolic blood pressure at 6 months with renal denervation. Our analysis substantiates 
the safety profile of the procedure o based on renal function at 6 months post procedure. Given the evidence of 
procedure-related factors, objective assessment of drug adherence, novel renal denervation techniques, and sham 
control study design affects the overall study outcomes; future clinical trials must account for these variances in 
order to better assess the effectiveness of renal denervation in patients with RH. Furthermore, the type of ablation 
therapy used and target sites for ablation (conventional versus branch renal artery ablation techniques) must be 
explored in future trials. Based on the current evidence, patients with resistant hypertension and no identifia-
ble secondary cause (renovascular or renal parenchymal disease, etc.), maximized on lifestyle interventions and 
medical therapy by a hypertension specialist may benefit from renal denervation with an experienced operator.
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